Cargando…
Old and new treatment targets in axial spondyloarthritis
Two main treatment targets in axial spondyloarthritis (axSpA) could be currently defined: (1) reduction of inflammation resulting in control of signs and symptoms such as pain and stiffness and (2) prevention or retardation of structural damage progression in the spine resulting in preservation of f...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632151/ https://www.ncbi.nlm.nih.gov/pubmed/26557376 http://dx.doi.org/10.1136/rmdopen-2015-000054 |
_version_ | 1782398971112587264 |
---|---|
author | Rios Rodriguez, Valeria Poddubnyy, Denis |
author_facet | Rios Rodriguez, Valeria Poddubnyy, Denis |
author_sort | Rios Rodriguez, Valeria |
collection | PubMed |
description | Two main treatment targets in axial spondyloarthritis (axSpA) could be currently defined: (1) reduction of inflammation resulting in control of signs and symptoms such as pain and stiffness and (2) prevention or retardation of structural damage progression in the spine resulting in preservation of functional status and improvement in the long-term outcome. A good control of signs and symptoms could be successfully achieved nowadays in the majority of patients treated with non-steroidal anti-inflammatory drugs (NSAIDs—the first-line therapy in axSpA) and with tumour necrosis factor (TNF) α blockers (the second-line therapy, if NSAIDs fail). Several pipeline drugs including interleukin (IL) 17 and IL-23 antagonists might be helpful in the immediate future in achievement of this treatment target in case of inefficacy of NSAIDs and TNFα blockers. Retardation of radiographical spinal progression in axSpA—disease modification—is currently a much more challenging task than a good symptom control. In this review, we discuss symptomatic and possible disease-modifying properties of current and forthcoming treatment options for axSpA. |
format | Online Article Text |
id | pubmed-4632151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46321512015-11-09 Old and new treatment targets in axial spondyloarthritis Rios Rodriguez, Valeria Poddubnyy, Denis RMD Open Proceedings from OsteoRheumatology 2014 Two main treatment targets in axial spondyloarthritis (axSpA) could be currently defined: (1) reduction of inflammation resulting in control of signs and symptoms such as pain and stiffness and (2) prevention or retardation of structural damage progression in the spine resulting in preservation of functional status and improvement in the long-term outcome. A good control of signs and symptoms could be successfully achieved nowadays in the majority of patients treated with non-steroidal anti-inflammatory drugs (NSAIDs—the first-line therapy in axSpA) and with tumour necrosis factor (TNF) α blockers (the second-line therapy, if NSAIDs fail). Several pipeline drugs including interleukin (IL) 17 and IL-23 antagonists might be helpful in the immediate future in achievement of this treatment target in case of inefficacy of NSAIDs and TNFα blockers. Retardation of radiographical spinal progression in axSpA—disease modification—is currently a much more challenging task than a good symptom control. In this review, we discuss symptomatic and possible disease-modifying properties of current and forthcoming treatment options for axSpA. BMJ Publishing Group 2015-08-15 /pmc/articles/PMC4632151/ /pubmed/26557376 http://dx.doi.org/10.1136/rmdopen-2015-000054 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Proceedings from OsteoRheumatology 2014 Rios Rodriguez, Valeria Poddubnyy, Denis Old and new treatment targets in axial spondyloarthritis |
title | Old and new treatment targets in axial spondyloarthritis |
title_full | Old and new treatment targets in axial spondyloarthritis |
title_fullStr | Old and new treatment targets in axial spondyloarthritis |
title_full_unstemmed | Old and new treatment targets in axial spondyloarthritis |
title_short | Old and new treatment targets in axial spondyloarthritis |
title_sort | old and new treatment targets in axial spondyloarthritis |
topic | Proceedings from OsteoRheumatology 2014 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632151/ https://www.ncbi.nlm.nih.gov/pubmed/26557376 http://dx.doi.org/10.1136/rmdopen-2015-000054 |
work_keys_str_mv | AT riosrodriguezvaleria oldandnewtreatmenttargetsinaxialspondyloarthritis AT poddubnyydenis oldandnewtreatmenttargetsinaxialspondyloarthritis |